Hope for boys with muscular dystrophy: 2-Year drug extension study seeks to control debilitating disease
Disease control
ENROLLING_BY_INVITATION
This study follows boys with Duchenne muscular dystrophy who previously received the experimental drug WVE-N531 to see how safe and effective it is over two years. All 175 participants will continue receiving monthly intravenous doses of the drug while researchers monitor their h…
Phase: PHASE2 • Sponsor: Wave Life Sciences Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC